Vectorite Biomedical

Vectorite Biomedical FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Vectorite Biomedical (4170.TWO) as of Nov 5, 2026 is -10.17 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 35.83 % — a change of -128.39% (lower).

FCF Conversion

-10.17 %

YoY

-128.39%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Vectorite Biomedical is 2025 -10.17 % . FCF Conversion Rate (FCF/EBITDA) of Vectorite Biomedical was 2024 35.83 % . It decreases by -128.39% lower compared to the previous year.

The Vectorite Biomedical FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
418.69 TWD
Jan 1, 2019
74.25 TWD
Jan 1, 2020
55.26 TWD
Jan 1, 2021
-808.66 TWD
Jan 1, 2022
-52.30 TWD
Jan 1, 2023
52.37 TWD
Jan 1, 2024
35.83 TWD
Jan 1, 2025
-10.17 TWD
The Vectorite Biomedical FCF Conversion history
YEARFCF ConversionYoY
-10.17 %-128.39%
35.83 %-31.58%
52.37 %-200.13%
-52.30 %-93.53%
-808.66 %-1,563.35%
55.26 %-25.57%
74.25 %-82.27%
418.69 %-1,866.84%
-23.70 %-126.72%
88.70 %-70.12%
296.88 %-309.08%
-141.99 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vectorite Biomedical Stock analysis

What does Vectorite Biomedical do? Xinpin Biomedical Co., Ltd. established Xinpin Biomedical Group with the concept of “preventing problems before it happens” and is headquartered in Taipei, New Taipei. The firm offers a range of services including immune cell collection, processing and storage, cell preparation safety testing, anti-cancer immunity testing, original design manufacturer or contract development and manufacturing organization services, related medical consulting, and laboratory quality management. Its product portfolio features dendritic cell vaccines and natural killer cell preparations designed for cancer treatment. Products are mainly sold domestically. Vectorite Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vectorite Biomedical stock

FCF Conversion Rate (FCF/EBITDA) of Vectorite Biomedical is -10.17 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Vectorite Biomedical changed from 35.83 % to -10.17 %, representing a -128.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Vectorite Biomedical since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Vectorite Biomedical with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Vectorite Biomedical

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Vectorite Biomedical